Phathom Pharmaceuticals, Inc. (PHAT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Phathom Pharmaceuticals, Inc. (PHAT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 56/100 — a percentile rank of Phathom Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $590.6M |
| P / S | 2.5× |
| EV / EBITDA | -14.3× |
| Gross margin | 82.9% |
| Operating margin | -17.0% |
| Net margin | -41.3% |
| Return on equity | 28.8% |
| ROIC | 11.3% |
| Revenue growth | 110.2% |
| Debt / equity | -0.5× |
| Dividend yield | 0.0% |
Is Phathom Pharmaceuticals, Inc. overvalued? P/S looks fair vs its 5-year range.
Independent of the events above — derived from Phathom Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact